Host genetic factors and vaccine-induced immunity to hepatitis B virus infection

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Hennig, Branwen J ^a,b   Fielding, Katherine ^a   Broxholme, John ^b   Diatta, Mathurin ^c   Mendy, Maimuna ^c   Moore, Catrin ^d   Pollard, Andrew J ^d   Rayco Solon, Pura ^a,c   Sirugo, Giorgio ^c   van der Sande, Marianne A ^c   Waight, Pauline ^c   Whittle, Hilton C ^c   Zaman, Syed M ^c   Hill, Adrian V ^b   Hall, Andrew J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; GAMMA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HLA ANTIGEN; INTERLEUKIN 10 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; STRESS ACTIVATED PROTEIN KINASE 1; HEPATITIS B ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CELL INTERACTION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMBIA; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEREDITY; HOST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFANT; MAJOR CLINICAL STUDY; MALE; PREDICTION; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS IMMUNITY; BIOSYNTHESIS; GENETICS; IMMUNOLOGY;

HEPATITIS B VIRUS;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS;

EID: 45049084890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001898     Document Type: Article

References (48)

1. WHO (2000) Hepatitis B fact sheet.
2. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, et al. (1991) Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia Lancet 337: 747-750.
3. Chotard J, Inskip HM, Hall AJ, Loik F, Mendy M, et al. (1992) The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 166: 764-768.
4. Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, et al. (1993) Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 341: 1129-1131.
5. Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, et al. (1994) Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 169: 1374-1376.
6. Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, et al. (1995). Longterm efficacy of continuing hepatitis B vaccinatibn in infancy in two Gambian villages. Lancet 345: 1089-1092.
7. Viviani S, Jack A, Hall AJ. Maine N, Mendy M, et al. (1999) Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17: 2946-2950.
8. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, et al. (2002) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Bmj 325: 569.
9. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hurt P, et al. (2006) Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 193: 1528-1535.
10. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179: 489-492.
11. Inskip HM, Hall AJ, Chotard J, Loik F, Whittle H (1991) Hepatitis B vaccine in the Gambian Expanded Programme on Immunization: factors influencing antibody response. Int J Epidemiol 20: 764-769.
12. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, et al. (2007) Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2: e753.
13. Lin TM, Chen CJ, Wu MM, Yang CS, Chen JS, et al. (1989) Hepatitis B virus markers in Chinese twins. Anticancer Res 9: 737-741.
14. Alper CA (1995) The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet 12: 171-181.
15. Kruger A, Adams P, Hammer J, Becher WO, Schneider PM, et al. (2005) Hepatitis B surface antigen presentation and HLA-DRB1*- lessons from twins and peptide binding studies. Clin Exp Immunol 140: 325-332.
16. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, et al. (2002) Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360: 991-995.
17. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, et al. (2004) Genetic regulation of immune responses to vaccines in early life. Genes Immun 5: 122-129.
18. Ovsyannikova IG, Jacobson RM, Poland GA (2004) Variation in vaccine response in normal populations. Pharmacogenomics 5: 417-427.
19. De Silvestri A, Pasi A, Martinetti M, Belloni C, Tinelli C, et al. (2001) Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun 2: 367-372.
20. Desombere I, Cao T, Gijbels Y, Leroux-Roels G (2005) Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation. Clin Exp Immunol 140: 126-137.
21. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G (1995) Norresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 154: 520-529.
22. Hatae K, Kimura A, Okubo R, Watanabe H, Erlich HA, et al. (1992) Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 22: 1899-1905.
23. Hobler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, et al. (1998) The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 59: 212-218.
24. Hohler T, Stradmann-Bellinghausen B, Starke R, Sanger R, Victor A, et al. (2002) C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 37: 387-392.
25. Martinetti M, De Silvestri A, Belloni C, Pasi A, Tinelli C, et al. (2000) Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 97: 234-240.
26. McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA (1997) Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50: 8-14.
27. Sullivan JS, Hanna JN (1999) A genetic market associated with non-response to recombinant hepatitis B vaccine by indigenous Australian children. J Paediatr Child Health 35: 412-413.
28. Vidan-Jeras B, Brinovec V, Jurca B, Levicnik Steyinar S, Jeras M, et al. (2000) The contribution of HLA-Class II antigens in humoral non-response and delayed response to HBsAG vaccination. Pflugers Arch 440: R188-189.
29. Milich DR, Leroux-Roels GG (2003) Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2: 248-257.
30. Thursz M (2001) MHC and the viral hepatitides. Qjm 94: 287-291.
31. Kimman TG, Vandebriel RJ, Hoebee B (2007) Genetic variation in the response to vaccination. Community Genet 10: 201-217.
32. Whittle HC, Bradley AK, McLauchlan K, Ajdukiewicz AB, Howard CR, et al. (1983) Hepatitis B virus infection in two Gambian villages. Lancet 1: 1203-1206.
33. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
34. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
35. Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3: 391-397.
36. Hohler T, Reuss E, Freitag CM, Schneider PM (2005) A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 42: 72-76.
37. Lindemann M, Barsegian V, Siffert W, Ferencik S, Roggendorf M, et al. (2002) Role of G protein beta3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination. Virology 297: 245-252.
38. Lindemann M, Virchow S, Ramann F, Barsegian V, Kreuzfelder E, et al. (2001) The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett 495: 8246.
39. Louagic H, Delanghc J, Desombere I, De Buyzere M, Hauser P, et al. (1993) Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine 11: 1188-1190.
40. Sleijffers A, Yucesoy B, Kashon M, Garssen J, De Gruijl FR, et al. (2003) Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation or immune responses after hepatitis B vaccination. J Immunol 170: 3423-3428.
41. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, et al. (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39: 978-988.
42. Yucesoy B, Sleijffers A, Kashon M, Garssen J, de Gruijl FR, et al. (2002) IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine 20: 3193-3196.
43. Yang SH, Lee CG, Park SH, Im SJ, Kim YM, et al. (2006) Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13: 1110-1117.
44. Vanlandschoot P, Roobrouck A, Van Houtte F, Leroux-Roels G (2002) Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocyLes. Biochem Biophys Res Commun 297: 486-491.
45. Arbour N, Naniche D, Homann D, Davis RJ, Flavell RA, et al. (2002) c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediaLed antiviral immunity. J Exp Med 195: 801-810.
46. Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guyre PM (2007) Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol 81: 663-671.
47. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, et al. (2005) Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract 201: 379-384.
48. Sun Z, Zhu Y, Stjernsward J, Hilleman M, Collins R, et al. (1991) Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect Prev 15: 313-318.